Message from Dr. Ramón Cacabelos.
EuroEspes celebrates a quarter of a century of service to the community. During these 25 years of history, via the EuroEspes Biomedical Research Center, EuroEspes Biotechnology (Ebiotec) and EuroEspes Publishing, EuroEspes’ professional staff have performed over 150 research projects, which have given rise to 1,500 scientific publications, several patents and the first World Guide for Pharmacogenomics.
Ebiotec is the EuroEspes Group’s Biotechnology Center, where basic research on Health Biotechnology is performed and where the exclusive nutraceutical bioproducts are manufactured, for their domestic and international distribution.
Our institutional commitment is centered on 5 priority areas: (i) genomic medicine applied to the prediction of risks and the early diagnosis of prevalent neurodegenerative and cardiovascular diseases; (ii) pharmacogenomics applied to the personalization of pharmacological treatment; (iii) the development and manufacture of nutraceutical bioproducts for the prevention and treatment of various pathologies; (iv) the implementation of nutrigenomic programs for the personalization of the diet for preventive and therapeutic purposes; and (v) the diffusion of scientific knowledge in the field of genomic medicine.
The nutraceutical bioproducts developed at Ebiotec by the application of non-denaturing biotechnological processes preserve all the biological properties of their natural source (be it marine, vegetable or animal). All Ebiotec’s products are supported by preclinical and clinical scientific documentation, are prophylactically oriented and display high therapeutic value as adjunctive therapy in various health problems (disruption of lipid metabolism, arteriosclerosis, neurodegenerative problems, cardio- and cerebrovascular disorders, immune system dysfunction, neoplastic processes).
Among our priorities is the search for efficient solutions to the serious problem posed by dementia (Alzheimer’s disease, vascular dementia), ictus and other degenerative problems of the nervous system, such as Parkinson’s disease. All these incapacitating diseases of the nervous system are the primary objective of our preventive and therapeutic programs with the development of vaccines and predictive genomic medicine and pharmacogenomic programs applied to the specific requirements of each person.
Our commitment to society is to place knowledge and biotechnology at the service of people’s well-being.
Manufacture of nutraceuticals
Industrial Lyophilization area
PROVISION OF SERVICES
Our clients can order any of our wide range of high-technology services via our website, by telephone, fax and/or e-mail. Our scientific and technical personnel will study each case personally, to provide the best solution.
Ebiotec distributed its products and services direct and/or via its partners at pharmacies, parapharmacies and herbalists.
At its headquarters in Corunna, Ebiotec is in the midst of a process of international growth by entering into distribution agreements with companies established in the food supplement, nutraceutical and OTC markets.